Endometriosis Treatment: Meta-Analysis of Pharmacological Clinical and Hormonal Outcomes
Overview
This systematic review and meta-analysis of 149 clinical trials evaluated hormonal and non-hormonal pharmacological treatments for endometriosis. Combined oral contraceptives, progestins (notably dienogest), GnRH analogues, LNG-IUS, and relugolix demonstrated significant reductions in pelvic pain and menstrual irregularities with high-quality evidence supporting their efficacy.
Background
Endometriosis is a chronic estrogen-dependent disorder characterized by ectopic endometrial-like tissue causing pelvic pain, dysmenorrhea, and infertility, affecting approximately 10% of women of reproductive age. Its pathogenesis involves hormonal imbalances, immune dysfunction, and genetic factors. Management aims to alleviate symptoms, improve fertility, and reduce recurrence, with pharmacological endocrine therapies being central due to their ability to modulate estrogen-dependent disease activity. Treatments include combined oral contraceptives, progestins, GnRH agonists and antagonists, and intrauterine systems, which act by suppressing ovarian steroidogenesis and reducing ectopic lesion growth.
Data Highlights
Treatment
Effect Size (SMD or RR)
95% Confidence Interval
p-value
Outcome
Combined Oral Contraceptives (COCs) & Progestins
-0.35 to -0.58 (SMD)
-0.90 to -0.08
<0.05
Pelvic pain and menstrual irregularities reduction
Dienogest (Progestin)
-0.58 (SMD)
-0.90 to -0.26
<0.001
Dysmenorrhea alleviation
Relugolix (Combination)
-0.72 (SMD)
-0.94 to -0.50
<0.001
Endometriosis-related pain reduction
GnRH Analogues
-0.65 (SMD)
-0.88 to -0.42
<0.001
Consistent pain reduction
LNG-IUS
0.51 (RR)
0.33–0.79
0.002
Reduced menorrhagia and recurrence post-surgery
Adjunctive Therapies (Antioxidants, NAC, Melatonin, Digital Therapeutics)
-0.40 to -0.62 (SMD)
Not specified
<0.05
Additional pain relief and quality-of-life improvement
Key Findings
Combined oral contraceptives and progestins significantly reduce pelvic pain and menstrual irregularities, with dienogest showing the greatest efficacy for dysmenorrhea.
GnRH analogues consistently decrease endometriosis-related pain by inducing a hypoestrogenic state.
LNG-IUS use is associated with decreased menorrhagia and lower recurrence rates after surgical treatment.
Adjunctive therapies such as antioxidants, N-acetylcysteine, melatonin, and digital therapeutics contribute additional pain reduction and quality-of-life benefits.
The majority of included studies demonstrated rigorous methodology (Jadad scores 3–5) and moderate-to-high certainty of evidence (GRADE criteria).
Clinical Implications
Hormonal therapies remain the cornerstone of endometriosis management, with treatment selection tailored to individual patient characteristics and tolerability to optimize clinical outcomes. Dienogest and GnRH analogues are effective options for pain control, while LNG-IUS offers benefits in reducing menorrhagia and recurrence. Adjunctive therapies may provide supplementary symptom relief and improve quality of life.
Conclusion
Pharmacological endocrine therapies effectively alleviate pain and menstrual symptoms in endometriosis, supported by high-quality evidence. Personalized treatment strategies based on patient-specific factors are essential to maximize therapeutic benefits.
References
Systematic Review and Meta-Analysis 2024 -- Endometriosis Treatment: Clinical and Hormonal Outcomes
